Anticoagulation in patients with heart failure

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 3, 2009, Pages 193-197

  Bhatia, R Sacha ^a,b,c   Ouzounian, Maral ^b,c   Tu, Jack V ^a,c,d   Liu, Peter P ^b,c,e   Lee, Douglas S ^a,b,c  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e CANADIAN INSTITUTES OF HEALTH RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DICOUMAROL; PLACEBO; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE ANEURYSM; HUMAN; HYPERCOAGULABILITY; INFLAMMATION; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MONOTHERAPY; NEUROENDOCRINE SYSTEM; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBUS; VALVULAR HEART DISEASE;

ANTICOAGULANTS; HEART FAILURE; HUMANS; THROMBOEMBOLISM; THROMBOSIS;

EID: 70349478604     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789105462     Document Type: Review

References (51)

1. Massie, B.M.; Shah, N.B. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am. Heart J., 1997, 133, 703.
2. Berry, C.; Murdoch, D.R; McMurray, J.J. Economics of chronic heart failure. Eur. J. Heart Fail., 2001, 3, 283.
3. Pulerwitz, T.; Rabbani, L.E.; Pinney, S.P. A rationale for the use of anticoagulation in heart failure management. J. Thromb. Thrombolysis, 2004, 17, 87.
4. Dunkman, W.B.; Johnson, G.R.; Carson, P.E.; Bhat, G.; Farrell, L.; Cohn, J.N. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation, 1993, 87, VI94.
5. Hunt, S.A.; Abraham, W.T.; Chin M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M.; Michl, K.; Oates, J.A.; Rahko, P.S.; Silver, M.A.; Stevenson, L.W.; Yancy, C.W.; Antman, E.M.; Smith, S.C. Jr.; Adams, C.D.; Anderson, J.L.; Faxon, D.P.; Fuster, V.; Halperin, J.L.; Hiratzka, L.F.; Jacobs, A.K.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure. J. Am. Coll. Cardiol., 2005, 46, e1.
6. Chong, A.Y.; Lip, G.Y. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response? Eur. J. Heart Fail., 2007, 9, 124.
7. Lip, G.Y.; Gibbs, C.R. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J. Am. Coll. Cardiol., 1999, 33, 1424.
8. Lip, G.Y.; Gibbs, C.R. Anticoagulation for heart failure in sinus rhythm. Cochrane Database Syst. Rev., 2001, 4, CD003336.
9. Loh, E.; Sutton, M.S.; Wun, C.C.; Rouleau, J.L.; Flaker, G.C.; Gottlieb, S.S.; Lamas, G.A.; Moye, L.A.; Goldhaber, S.Z.; Pfeffer, M.A. Ventricular dysfunction and the risk of stroke after myocardial infarction. N. Engl. J. Med., 1997, 336, 251.
10. Dotsenko, O.; Kakkar, V.V. Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. J. Thromb. Haemost., 2007, 5, 224.
11. Jafri, S.M. Hypercoagulability in heart failure. Semin. Thromb. Hemost., 1997, 23, 543.
12. Sharma, N.D.; McCullough, P.A.; Philbin, E.F.; Weaver, W.D. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest, 2000, 117, 314.
13. Gottdiener, J.S.; Gay, J.A.; VanVoorhees, L.; DiBianco, R.; Fletcher, R.D. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am. J. Cardiol., 1983, 52, 1281.
14. Ho, K.K.; Pinsky, J.L.; Kannel, W.B.; Levy, D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol., 1993, 22, 6A.
15. Loscalzo, J. What we know and don't know about L-arginine and NO. Circulation, 2000, 101, 2126.
16. Moncada, S. Nitric oxide in the vasculature: physiology and pathophysiology. Ann. N. Y. Acad. Sci., 1997, 811, 60-67; discussion 67-69.
17. Katz, S.D. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr. Opin. Cardiol., 1997, 12, 259.
18. Treasure, C.B.; Vita, J.A.; Cox, D.A.; Fish, R.D.; Gordon, J.B.; Mudge, G.H.; Colucci, W.S.; Sutton, M.G.; Selwyn, A.P.; Alexander, R.W.; Ganz P. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation, 1990, 81, 772.
19. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988, 332, 411.
20. Levin, E.R. Endothelins. N. Engl. J. Med., 1995, 333, 356.
21. Wei, C.M.; Lerman, A.; Rodeheffer, R.J.; McGregor, C.G.; Brandt, R.R.; Wright, S.; Heublein, D.M.; Kao, P.C.; Edwards, W.D.; Burnett, J.C. Jr. Endothelin in human congestive heart failure. Circulation, 1994, 89, 1580.
22. Sbarouni, E.; Bradshaw, A.; Andreotti, F.; Tuddenham, E.; Oakley, C.M.; Cleland, J.G. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Am. Heart J., 1994, 127, 607.
23. Lip, G.Y.; Conway, D.S. Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. J. Am. Coll. Cardiol., 2001, 38, 2133.
24. Lip, G.Y.; Chung, I. Vascular endothelial growth factor and angiogenesis in heart failure. J. Card. Fail., 2005, 11, 285.
25. Dibbs, Z.; Kurrelmeyer, K.; Kalra, D.; Seta, Y.; Wang, F.; Bozkurt, B.; Baumgarten, G.; Sivasubramanian, N; Mann, D.L. Cytokines in heart failure: pathogenetic mechanisms and potential treatment. Proc. Assoc. Am. Physicians, 1999, 111, 423.
26. Paulus, W.J. Cytokines and heart failure. Heart Fail. Monit., 2000, 1, 50.
27. Chin, B.S.; Chung, N.A.; Gibbs, C.R.; Blann, A.D.; Lip, G.Y. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart failure. Am. J. Cardiol., 2002, 90, 1258.
28. O'Connor, C.M.; Gurbel, P.A.; Serebruany, V.L. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am. J. Cardiol., 1999, 83, 1345.
29. Gibbs, C.R.; Blann, A.D.; Watson, R.D.; Lip, G.Y. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy. Circulation, 2001, 103, 1746.
30. Swales, J.D. The renin-angiotensin system as a target for therapeutic intervention. J. Cardiovasc. Pharmacol., 1994, 24(Suppl. 2), S1-5.
31. Holtz, J. Pathophysiology of heart failure and the renin-angiotensin-system. Basic Res. Cardiol., 1993, 88(Suppl. 1), 183.
32. Jafri, S.M.; Ozawa, T.; Mammen, E.; Levine, T.B.; Johnson, C.; Goldstein, S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur. Heart J., 1993, 14, 205.
33. Stumpf, C.; Lehner, C.; Eskafi, S.; Raaz, D.; Yilmaz, A.; Ropers, S.; Schmeisser, A.; Ludwig, J.; Daniel, W.G.; Garlichs, C.D. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur. J. Heart Fail., 2003, 5, 629.
34. Lip, G.Y.; Pearce, L.A.; Chin, B.S.; Conway, D.S.; Hart, R.G. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation. Heart, 2005, 91, 759.
35. Wolinsky, J.S. The PROMiSe trial: baseline data review and progress report. Mult. Scler., 2004, 10(Suppl. 1), S65-71, discussion S71-62.
36. Witt, B.J.; Brown, R.D. Jr.; Jacobsen, S.J.; Weston, S.A.; Ballman, K.V.; Meverden, R.A.; Roger, V.L. Ischemic stroke after heart failure: a community-based study. Am. Heart J., 2006, 152, 102.
37. Appelros, P. Heart failure and stroke. Stroke, 2006, 37, 1637.
38. Al-Khadra, A.S.; Salem, D.N.; Rand, W.M.; Udelson, J.E.; Smith, J.J.; Konstam, M.A. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J. Am. Coll. Cardiol., 1998, 31, 419.
39. Roberts, W.C.; Siegel, R.J.; McManus, B.M. Idiopathic dilated cardiomyopathy: analysis of 152 necropsy patients. Am. J. Cardiol., 1987, 60, 1340.
40. Uretsky, B.F.; Thygesen, K.; Armstrong, P.W.; Cleland, J.G.; Horowitz, J.D.; Massie, B.M.; Packer, M.; Poole-Wilson, P.A.; Ryden, L. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation, 2000, 102, 611.
41. Darze, E.S.; Latado, A.L.; Guimaraes, A.G.; Guedes, R.A.; Santos, A.B.; de Moura, S.S.; Passos, L.C. Acute pulmonary embolism is an independent predictor of adverse events in severe decompensated heart failure patients. Chest, 2007, 131, 1838.
42. Grubman, E.M.; Pavri, B.B.; Shipman, T.; Britton, N.; Kocovic, D.Z. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J. Am. Coll. Cardiol., 1998, 32, 1056.
43. Anderson, G.M.; Hull, E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am. Heart J., 1950, 39, 697.
44. Harvey, W.P.; Finch, C.A. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N. Engl. J. Med., 1950, 242, 208.
45. Cleland, J.G.; Ghosh, J.; Freemantle, N.; Kaye, G.C.; Nasir, M.; 8Clark, A.L.; Coletta, A.P. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail., 2004, 6, 501.
46. Cleland, J.G.; Findlay, I.; Jafri, S.; Sutton, G.; Falk, R.; Bulpitt, C.; Prentice, C.; Ford, I.; Trainer, A.; Poole-Wilson, P.A. The Warfarin/ Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am. Heart J., 2004, 148, 157.
47. Cokkinos, D.V.; Haralabopoulos, G.C.; Kostis, J.B.; Toutouzas, P.K. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur. J. Heart Fail., 2006, 8, 428.
48. Pullicino, P.; Thompson, J.L.; Barton, B.; Levin, B.; Graham, S.; Freudenberger, R.S. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J. Card. Fail., 2006, 12, 39.
49. Serebruany, V.L.; Malinin, A.I.; Jerome, S.D.; Lowry, D.R.; Morgan, A.W.; Sane, D.C.; Tanguay, J.F.; Steinhubl, S.R.; O'Connor C.M. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am. Heart J., 2003, 146, 713.
50. Koniaris, L.S.; Goldhaber, S.Z. Anticoagulation in dilated cardiomyopathy. J. Am. Coll. Cardiol., 1998, 31, 745.
51. Visser, L.E.; Bleumink, G.S.; Trienekens, P.H.; Vulto, A.G.; Hofman, A.; Stricker, B.H. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. Br. J. Haematol., 2004, 127, 85.